Search

Displaying results 3071 - 3080 of 8575 in total
  1. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

  2. Drug

    BMS-911543

    go.drugbank.com/drugs/DB12591
    Investigational

    BMS-911543 has been used in trials studying the treatment of Cancer.

  3. Drug

    Carboprost tromethamine

    go.drugbank.com/drugs/DB00429
    ApprovedInvestigational

    A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.

  4. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...

  5. Drug

    Indecainide

    go.drugbank.com/drugs/DB00192
    Approved

    Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics

  6. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    While artemether results in rapid defervescence, parasite clearance, and clinical improvement, it also has a relatively high recrudescence rate when used as monotherapy. … Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate.

  7. Drug

    Indium In-111 imciromab pentetate

    go.drugbank.com/drugs/DB09339
    ApprovedWithdrawn

    Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.

  8. Drug

    QR-333

    go.drugbank.com/drugs/DB05533
    Investigational

    QR-333 has been investigated as a treatment for diabetic peripheral neuropathy.

  9. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent. … It has since been demonstrated that the agent possesses activity against amoebas and yaws.

  10. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.